Showing 1 - 10 of 38,526
Healthcare reform has placed increasing pressure on anaesthetists to consider the costs of current anaesthesia strategies. Although the cost of anaesthesia constitutes only a small proportion of total healthcare costs, anaesthetic drug expenditures have been a focus of cost-containment efforts....
Persistent link: https://www.econbiz.de/10005590276
Clinical and economic factors that are important to consider when selecting anaesthesia for day-case surgery can differ from those for inpatient anaesthesia. Patients undergoing day-case surgery tend to be healthier and have shorter durations of surgery. They expect less anxiety before surgery,...
Persistent link: https://www.econbiz.de/10005243102
Open-heart surgery (OHS) is performed to bypass occluded arteries, replace malfunctioning cardiac valves or correct congenital abnormalities. The average cost of OHS varies from $US25 057-$US79 795 (1997 values). The objective of this paper was to review economic studies of pharmacological...
Persistent link: https://www.econbiz.de/10005404885
Most pharmacoeconomic studies of mycophenolate mofetil have focused on its use as part of maintenance immunosuppression for renal transplantation, involving short-term (3-12 months) time frames. In general, mycophenolate mofetil reduced the treatment costs for rejection episodes and graft...
Persistent link: https://www.econbiz.de/10005404609
Objective: To identify patterns of care and associated costs for typical patients with chronic obstructive pulmonary disease (COPD) in a US managed-care setting. Design: Retrospective analysis of administrative data from a proprietary managed-care research database. Patients: 6371 patients with...
Persistent link: https://www.econbiz.de/10005404621
Many health plans and providers rely on return on investment (ROI) to determine the value of a disease management programme. ROI, however, is not the most meaningful measure of the true value of a programme. Depending on the methods used to calculate costs and determine the size of the...
Persistent link: https://www.econbiz.de/10005404636
Paclitaxel belongs to the group of antitumor agents called the taxanes. Its efficacy in advanced ovarian cancer has been established in large, randomized phase III clinical trials. When used in combination with cisplatin for first-line treatment of advanced ovarian cancer, it is superior to...
Persistent link: https://www.econbiz.de/10005404683
As physicians become more aware of the need to treat anaemia in their patients with cancer, they have to consider 2 treatment options: red blood cell transfusion or recombinant human erythropoietin [epoetin alfa; epoetin beta]. Healthcare systems are under increasing pressure to lower costs while...
Persistent link: https://www.econbiz.de/10005404720
This article describes the critical ingredients of the assertive community treatment (ACT) model for people with severe mental illness and then reviews the evidence regarding its effectiveness and cost effectiveness. ACT is an intensive mental health program model in which a multidisciplinary...
Persistent link: https://www.econbiz.de/10005404730
Contemporary asthma management guidelines list inhaled corticosteroids as the preferred controller medication for patients with persistent asthma. Despite the availability of explicit guidelines, there is evidence that these agents are underused and that guidelines are not always adhered to....
Persistent link: https://www.econbiz.de/10005404779